Analytical Data
-
Gene name
Claudin-11/CLDN11
- Application
-
Alternative Names
OSP; OTM; Oligodendrocyte Transmembrane Protein
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O75508
-
Expression Region
Val23~Arg82
-
Molecular Weight
12kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Claudin-11 (CLDN11) is a crucial tight junction protein predominantly expressed in the central nervous system, particularly in oligodendrocytes, where it plays a vital role in maintaining the integrity of blood-brain barriers and facilitating myelination of nerve fibers. Its unique structure, characterized by four transmembrane domains, allows it to promote cell-cell adhesion and regulate paracellular permeability. The study of CLDN11 is essential, as its dysfunction has been implicated in various neurological disorders, including multiple sclerosis and other demyelinating diseases. Recent research has focused on the recombinant production of CLDN11 to investigate its functional properties and interactions in cell culture systems, enabling a better understanding of its role in neurobiology. The development of recombinant CLDN11 protein also holds promise for potential therapeutic applications, such as designing targeted treatments for conditions associated with tight junction dysfunction. Overall, understanding the molecular mechanisms involving CLDN11 is critical for advancing our knowledge of central nervous system health and disease.
